Kyverna Therapeutics News and Activities

View the org chart displaying its 35 main executives

Most searched biographies at Kyverna Therapeutics

• Warner Biddle, Chief Executive Officer and Director
• Mert Aktar, Director
• Sravan Emany, Director

Popular executive movements at Kyverna Therapeutics

• Nancy Boman, Chief Regulatory Officer, will leave the company on Aug. 3, 2026  (posted on July 10 2026).
• Ritesh Srivastava has joined the company as Chief Legal and Compliance Officer  (posted on June 22 2026).
• Nadia Dac has joined the company as Chief Commercial Officer  (posted on May 5 2026).

Click here to view some more movements at Kyverna Therapeutics

Create your alert
to follow the executive moves at Kyverna Therapeutics.

Kyverna Therapeutics has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Kyverna Therapeutics

• News Releases | Kyverna Therapeutics
• Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis | Kyverna Therapeutics
• Kyverna Therapeutics Congratulates Prof. G. Schett et al. on the Publication of a Case Series Follow-up of 15 Patients Living with Autoimmune Disease Treated With CAR T-Cell Therapy | Kyverna Therapeutics
• Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Kyverna Therapeutics
• Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering | Kyverna Therapeutics
• Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis | Kyverna Therapeutics
• Kyverna Therapeutics Announces First Publication of Ingenui-T, a Novel CAR T-Cell Vein-to-Vein Manufacturing Process | Kyverna Therapeutics
• Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial | Kyverna Therapeutics
• Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis | Kyverna Therapeutics
• Kyverna Therapeutics Announces Collaboration with Charité to Fund Research into B-Cell and Plasma Cell-Targeting Therapies in Patients with Autoimmune Diseases | Kyverna Therapeutics
• View more press releases Close

Social media about Kyverna Therapeutics

• Kyverna Therapeutics on Wikipedia, Google News & Yahoo Finance
• Kyverna Therapeutics on LinkedIn, X (Twitter) & YouTube